Seamus (J. L. P.) Thompson, PhD, has extensive experience in implementing methodologically innovative clinical trials in close collaboration with clinical leaders using state-of-the-art data management systems. Dr. Thompson directs the Statistical Analysis Center for Clinical Trials (SAC) within the Department of Biostatistics, which offers each trial a dedicated center providing all needed statistical and data management resources and a comprehensive website and web-based trial management capabilities. This approach has allowed the SAC to efficiently apply advanced trial designs developed by Biostatistics faculty members in a series of NIH-funded trials including WARSS (the Warfarin versus Aspirin for Recurrent Stroke Study, which employed a double-blinding algorithm developed by Dr. Thompson); TNK-S2B, comparing two interventions for acute stroke; and QALS, for the neurodegenerative disorder ALS. The largest SAC trial, WARCEF (Warfarin Versus Aspirin for low Cardiac Ejection Fraction), has recruited over 1800 patients in nine countries. The SAC also provides comprehensive statistical and data management capabilities for many national and international projects in epidemiology, including Arsenic Exposure in Bangladesh; the World Trade Center Research Program; the Puerto Rican Asthma Study; Diabetes Mellitus and Periodontal Disease in Children; and HIV in South Africa. Many of these projects originate in the NIEHS Center for Environmental Health in Northern Manhattan, where Dr. Thompson is currently Co-Director of the Integrative Health Sciences Core.
Areas of Expertise
Select Urban Health Activities
Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction-STAT: As Statistical Principal Investigator for the WARCEF trial, Dr. Thompson is responsible for the Statistical Analysis and Anticoagulation Data Management Center for this international, multi-center, double-blind, randomized clinical trial to determine whether warfarin or aspirin is better at preventing stroke and death in patients with reduced cardiac ejection fraction.
TNK-S2B: TNK-S2B trial is a multi-center, double-blind, randomized, "seamless" phase II/III study of tenectaplase (TNK) versus standard dose alteplase for treatment of patients with acute ischemic stroke within three hours of onset. As Statistical Principal Investigator Dr Thompson supervises the Data Management Center for TNK, which coordinates the data management and quality control activities of the study sites, and for the analytical and statistical support that enables the investigators to successfully complete the proposed clinical trial.
Integrative Health Sciences Core of the NIEHS Center for Environmental Health in Northern Manhattan (CEHNM): The mission of CEHNM is to understand and prevent the environmental components of disease. As Co-Director of the Integrative Health Sciences Core, Dr. Thompson is responsible for providing consultative expertise in study design, execution, and statistical analysis to investigators who are planning or conducting research through the Center.
Haley E, Thompson J, Levin B, Davis S, Lees K, Pittman J, DeRosa J, Ordronneau P, Brown D, Sacco R Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies Stroke 36 1006-1010 2005
Thompson, J., Fleiss, J., James, K. A Test of an Algorithm for Simulating Prothrombin Times in a Double-Blind Anticoagulation Drug Trial Annals of Neurology 36 305-306 1994
Mohr J, Thompson J, Lazar R, Levin B, Sacco R, Furie K, Kistler J, Albers G, Pettigrew L, Adams H, Jackson C, Pullicino P, for the Warfarin-Aspirin Recurrent Stroke Study Group A Comparison of Warfarin and Aspirin for the prevention of recurrent ischemic stroke New Engl J Med 345 1444-1451 2001
The GAIN Americas Investigators Glycine antagonist in neuroprotection for patients with acute stroke. GAIN Americas: a randomized controlled trial. JAMA 285 1719-1728 2001
Levine, S, Brey R, Tilley B, Thompson J, Sacco R, Sciacca R, Murphy A, Lu Y, Costigan T, Rhine C, Levin B, Triplett D, Mohr J Antiphospholipid Antibodies and Subsequent Thrombo-Occlusive Events in Patients with Ischemic Stroke. JAMA 291 576-584 2004
Thompson, J, Levy G Missing Data Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 5 (Supp 1) 48-51 2004
Furie, K, Rosenberg R, Thompson J, Bauer K, Mohr J, Rosner B, Sciacca R, Barzegar S, Thornell B, Costigan T, Kistler J Thrombin Generation in Non-Cardioembolic Stroke Subtypes: The Hemostatic System Activation Study Neurology 63 777-784 2004
Pullicino, P, Halperin J, Thompson J Stroke In Patients With Heart Failure And Reduced Left Ventricular Ejection Fraction. Neurology 54 288-294 2000
Thompson, J., Yager, T., Martin, J. Estimated Condom Failure and Frequency of Condom Use among Gay Men American Journal of Public Health 83 1409-1413 1993
Kaufmann, P, Levy G, Thompson J, DelBene M, Battista V, Gordon P, Rowland L, Levin B, Mitsumoto H The ALSFRSr predicts survival time in an ALS clinic population Neurology 64 38-43 2005
Buchsbaum, R., Kaufmann, p., Barsdorf, A., Arbing, R., Montes, J., and Thompson, J., for the QALS Study Group. Web-based data management for a phase II clinical trial in ALS (web publication ahead of print) DOI 10.1080/17482960802378998 09 Amyotrophic Lateral Sclerosis 2008
Thompson, J., and Quets, G. Genocide and Social Conflict: A Partial Theory and a Comparison Research in Social Movements, Conflicts, and Change 12 245-266 1990
Levy, G., Kaufmann, P., Buchsbaum, R., Montes, J., Barsdorf, A., Arbing, R., Battista, V., Zhou, X., Mitsumoto, H., Levin, B., and Thompson, J. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS Neurology 66 660-663 2006